Compare Abeona Therapeutics Inc (ABEO) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Brookfield Infrastructure Partners LP — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Brookfield Infrastructure Partners LP trades at $37.17 (market cap $16.97B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 45.5× Abeona Therapeutics Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.94% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BIP | |
|---|---|---|
Market Cap | $373.32M | $16.97B |
Sector | Health | Industrials |
52-Week High | $7.23 | $40.08 |
52-Week Low | $4.17 | $29.81 |
Enterprise Value | $228.22M | $78.64B |
Dividend Yield | — | 4.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Brookfield Infrastructure Partners (BIP) trades at $37.31, up 0.81% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock carries a high P/E of 56.53 but attractive P/S of 0.71 and EV/EBITDA of 7.53. Recent earnings show volatility with two misses in the last three quarters, though Q2 2026 results are pending. The company maintains strong cash flow from operations of $6.0 billion and recently declared a $0.46 dividend.
BIP offers value through its discounted valuation and 5% yield, supported by inflation-linked contracts and infrastructure assets. However, risks include recent earnings misses, high debt levels, and sensitivity to interest rates. Analyst consensus is strongly bullish with a $45.50 price target, suggesting 22% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
